We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+29.16%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$536M
Cap. Flow
+$287M
Cap. Flow %
14.23%
Top 10 Hldgs %
41.55%
Holding
100
New
24
Increased
34
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$52.5M
2
MDT icon
Medtronic
MDT
+$51M
3
ISRG icon
Intuitive Surgical
ISRG
+$45.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$37.4M
5
DXCM icon
DexCom
DXCM
+$32.3M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$63.9M
2
THC icon
Tenet Healthcare
THC
+$40.4M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$30.1M
4
BTSG icon
BrightSpring Health Services
BTSG
+$13.4M
5
PFE icon
Pfizer
PFE
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$21.4B
$218M 10.8%
1,250,000
-350,000
-22% -$63.9M
RVMD icon
2
Revolution Medicines
RVMD
$41.1B
$95.6M 4.75%
1,200,000
+800,000
+200% +$52.5M
VERA icon
3
Vera Therapeutics
VERA
$2.15B
$91.2M 4.53%
1,800,000
+100,000
+6% +$3.55M
CYTK icon
4
Cytokinetics
CYTK
$10.7B
$89M 4.42%
1,400,000
– –
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.3B
$81M 4.02%
105,000
+55,000
+110% +$37.4M
MDT icon
6
Medtronic
MDT
$110B
$64.8M 3.22%
675,000
+525,000
+350% +$51M
ISRG icon
7
Intuitive Surgical
ISRG
$130B
$62.3M 3.09%
110,000
+85,000
+340% +$45.3M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.26B
$50.8M 2.52%
475,000
+255,000
+116% +$27M
ALHC icon
9
Alignment Healthcare
ALHC
$2.8B
$43.5M 2.16%
2,200,000
+600,000
+38% +$10.8M
CAH icon
10
Cardinal Health
CAH
$54.7B
$41.1M 2.04%
200,000
+70,000
+54% +$13.2M
CVS icon
11
CVS Health
CVS
$133B
$39.7M 1.97%
500,000
+300,000
+150% +$23.7M
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.81B
$37.2M 1.85%
1,500,000
– –
GKOS icon
13
Glaukos
GKOS
$10.1B
$36.7M 1.82%
325,000
+225,000
+225% +$21.5M
NVS icon
14
Novartis
NVS
$291B
$34.5M 1.71%
250,000
+50,000
+25% +$6.55M
DXCM icon
15
DexCom
DXCM
$32.8B
$33.2M 1.65%
+500,000
New +$32.3M
AZN icon
16
AstraZeneca
AZN
$241B
$32.2M 1.6%
175,000
+25,000
+17% +$4.38M
CYTK icon
17
CALL
Cytokinetics
CYTK
$10.7B
$31.8M 1.58%
500,000
-250,000
-33% -$15.6M
TEVA icon
18
Teva Pharmaceuticals
TEVA
$40.1B
$31.2M 1.55%
+1,000,000
New +$24.6M
PEN icon
19
Penumbra
PEN
$12.8B
$31.1M 1.54%
100,000
+50,000
+100% +$13.8M
TFX icon
20
Teleflex
TFX
$6.2B
$30.5M 1.51%
+250,000
New +$30.3M
BTSG icon
21
BrightSpring Health Services
BTSG
$12.4B
$28.1M 1.39%
750,000
-400,000
-35% -$13.4M
EW icon
22
Edwards Lifesciences
EW
$51.6B
$27.7M 1.38%
325,000
+125,000
+63% +$10.3M
MLYS icon
23
Mineralys Therapeutics
MLYS
$2.34B
$27.2M 1.35%
750,000
-750,000
-50% -$30.1M
CNC icon
24
Centene
CNC
$31.7B
$26.7M 1.33%
650,000
+250,000
+63% +$9.36M
COO icon
25
Cooper Companies
COO
$14.6B
$26.6M 1.32%
325,000
+230,000
+242% +$17.2M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Integral Health Asset Management held 100 positions worth $2.01B, up 36% from $1.48B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Integral Health Asset Management deployed $287M of net new capital in Q4 2025, opening 24 new positions and adding to 34 existing holdings. Its largest new stake was DexCom: 500,000 shares worth $33.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $63.9M trimmed.

  • Integral Health Asset Management's largest Q4 2025 buy was DexCom: 500,000 shares worth $33.2M.
  • Integral Health Asset Management added most to Revolution Medicines in Q4 2025, an estimated $52.5M increase.
  • Integral Health Asset Management's biggest Q4 2025 reduction was Insmed, cutting an estimated $63.9M.
  • Integral Health Asset Management fully exited Pfizer in Q4 2025, selling an estimated $12.7M.
  • Integral Health Asset Management's ten largest holdings make up 42% of its $2.01B portfolio in Q4 2025.
  • Integral Health Asset Management opened 24 new positions and closed 14 in Q4 2025.
  • Integral Health Asset Management's portfolio value rose 36% quarter-over-quarter to $2.01B.

Based on Integral Health Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.